- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Banking and Institutional Finance
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Franchise and Hospitality
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Crisis Management
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- The New Administration: Enforcement and Legislative Impact
- Careers
- News & Insights
- About
- Languages
Insights 13 results
Newsletter
March 14, 2022
Health Headlines– March 14, 2022
Client Alert
February 7, 2022
A Pandemic Silver Lining: FDA’s New Guidance on Using Digital Health Technologies for Clinical Investigations
Client Alert
January 26, 2022
Spotlight on PFAS and Other Substances in Cosmetics Likely to Grow in 2022
Article · Source: Law360
January 25, 2022
How New Laws Could Tighten FDA Regulation Of Cosmetics
Client Alert
October 18, 2021
HHS Continues Focus on Women's Health: AHRQ Calls for Data on Telehealth for Women
Client Alert
Client Alert
March 15, 2021
The Establishment of the White House Gender Policy Council and Its Implications for FDA Initiatives and Priorities
Article · Source: The New York Law Journal
March 11, 2021
The Importance of Epidemiology To Contextualize Safety Signals Associated With Women's Health Products
Client Alert
December 28, 2020
California Medicaid Set to Lose $200 Million in Funding Next Quarter for its Universal Abortion Coverage Mandate
Client Alert
October 6, 2020
FDA Announces Updates to Two Guidance Documents Concerning Breast Implant Safety and Transparency
Client Alert
September 1, 2020
FDA Continues its Focus on Breast Implant Safety and Transparency with an Eye Toward Improving Regulatory Decision-Making
Article · Source: Bloomberg Law
August 21, 2020
How To Launch a Femtech/Telehealth Start Up